UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No.__)
______________________
Filed by the Registrant
Filed by a party other than the Registrant
Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material under § 240.14a-12
CERUS CORPORATION
(Name of Registrant as Specified In Its Charter)
N/A
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
No fee required
Fee paid previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
Supplemental information Regarding Proposal No. 2 – Approval of the Amendment and Restatement of the Company’s 2024 Equity Incentive Plan
In Proposal No. 2 (“Proposal No. 2”) of the proxy statement (the “Proxy Statement”) for the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Cerus Corporation (“Cerus” or the “Company”), to be held on Tuesday, June 3, 2025 at 9:00 a.m. Pacific time, we are requesting that our stockholders approve the amendment and restatement of our 2024 Equity Incentive Plan (the “2024 Plan”, and as amended and restated by the Board in March 2025, the “Amended and Restated 2024 Plan”).
We are providing this supplement to the Proxy Statement (this “Supplement”) to correct an inadvertent error in the table that appears in Proposal No. 2 on page 25 of the Proxy Statement (the “Overhang Table”) and to supplement the disclosure provided in Proposal No. 2. We urge you to read the Proxy Statement and this Supplement in their entirety. Except as specifically amended or supplemented by the information contained in this Supplement, all information set forth in the Proxy Statement remains unchanged.
Capitalized terms used but not otherwise defined in this Supplement shall have the meanings provided to them in the Proxy Statement.
Overhang Table
We are providing this Supplement to correct the total number of shares of common stock subject to outstanding stock options reported in the Overhang Table, which number of shares was erroneously overstated in the Proxy Statement. In this regard, the total number of shares of common stock subject to outstanding stock options as of April 1, 2025 was actually 10,759,078 shares, rather than 28,912,100 shares as erroneously overstated in the Proxy Statement. The revised Overhang Table, which reflects the correct number of shares of common stock subject to outstanding stock options as of April 1, 2025 and provides certain other information regarding our equity incentive plans, is set forth below.
|
|
As of April 1, 2025
|
|
|
Total number of shares of common stock subject to outstanding stock options(1) |
|
|
10,759,078 |
|
Weighted-average exercise price of outstanding stock options |
|
$ |
5.189 |
|
Weighted-average remaining term of outstanding stock options |
|
|
3.84 years |
|
Total number of shares of common stock subject to outstanding full value awards |
|
|
18,153,022 |
|
Total number of shares of common stock available for grant under the 2024 Plan |
|
|
4,250,869 |
|
Total number of shares of common stock available for grant under other equity incentive plans(2) |
|
|
— |
|
|
|
|
|
|
|
|
|
As of April 11, 2025 (the Record Date) |
|
Total number of shares of common stock outstanding(3) |
|
|
191,160,480 |
|
Per-share closing price of common stock as reported on Nasdaq Global Market |
|
$ |
1.38 |
|
(1) |
Such outstanding stock options are not entitled to any dividends or dividend equivalent rights. As of April 1, 2025, there were no other outstanding appreciation awards. |
(2) |
We currently have awards outstanding under the Inducement Plan, but as a result of the amendment and restatement of the 2008 Plan at our 2017 Annual Meeting of Stockholders, no additional awards may be granted under the Inducement Plan; accordingly, for purposes of the table above, no shares remained available for issuance under the Inducement Plan as of April 1, 2025. |
(3) |
Excludes 291,932 treasury shares. |
Why You Should Vote to Approve the Amended and Restated 2024 Plan (Proposal No. 2)
We Are Mindful of the Need to Balance Attraction and Retention of Talent with Dilution Considerations
We continue to believe that equity awards are a vital part of our overall compensation program. Our compensation philosophy reflects broad-based eligibility for equity awards, and we grant equity awards to substantially all of our employees. However, we recognize that equity awards dilute existing stockholders. We therefore carefully and thoughtfully manage our equity compensation program, balancing attraction, retention, and incentivization of our employees, non-employee directors, and consultants against dilution considerations.
The following table provides detail regarding our full dilution and the potential dilution resulting from the proposed share increase of 10,000,000 shares under the Amended and Restated 2024 Plan, in each case as of April 1, 2025:
Number of Shares Subject to Outstanding Stock Options(1) |
Number of Shares Subject to Outstanding Full Value Awards(1) |
Number of Shares Remaining Available for Future Grants(1)(2) |
Proposed Share Increase(3) |
Shares of Common Stock Outstanding (1) |
Full Dilution (1)(4) |
Potential Dilution from Proposed Share Increase(5) |
Peer Group Median Dilution(6) |
10,759,078 |
18,153,022 |
4,250,869 |
10,000,000 |
191,449,262 |
14.8% |
18.4% |
24.8% |
As of April 1, 2025, our full dilution of approximately 14.8% was below the 25th percentile of our compensation peer group. This is despite the fact that all shares underlying our outstanding stock options are underwater as of the date of this Supplement, which we believe provides executives and employees with added incentive to increase our stock price and create stockholder value.
The proposed share increase of 10,000,000 shares under the Amended and Restated 2024 Plan would modestly increase our full dilution to approximately 18.4%, which would keep our dilution below the 25th percentile of our compensation peer group and well below the median dilution of our peers as of December 31, 2024 (24.8%). We believe the additional shares will provide us with sufficient shares of our common stock to support at least one year of equity awards at our current market value, with a reasonable buffer to support unplanned events such as significant changes to our leadership team or headcount. We also believe the number of additional shares requested for issuance under the Amended and Restated 2024 Plan represents a reasonable amount of potential additional equity dilution based on peer data.
We Manage Our Equity Award Usage Carefully
We are committed to effectively monitoring our equity compensation share reserve, including our “burn rate,” in a manner intended to maximize stockholders’ value by granting the appropriate number of equity awards necessary to attract, reward, and retain employees, non-employee directors, and consultants. As further described in Proposal No. 2, our three-year average burn rate for fiscal years 2022 through 2024 was 4.07%, placing our burn rate during such period between the 25th and 50th percentiles of our compensation peer group.
We have taken several actions in recent years to responsibly manage our equity award usage. As further described in the section entitled “2024 Long-Term Incentive Compensation” within the “Compensation Discussion and Analysis” section of the Proxy Statement, since 2023, our Compensation Committee has utilized a premium to the current trading price of our common stock to determine the number of shares for each equity award granted to our executive officers and non-employee directors resulting from the approved dollar amount, which has resulted in fewer shares being awarded and therefore reduced the dilutive impact of the awards. In addition, since 2023, we have also granted our time-based equity awards solely in the form of RSU awards rather than a mix of options and RSUs—time-based RSU awards generally cover fewer shares than stock options that we would otherwise grant to
deliver a similar value to a grantee, thereby resulting in less dilution to our stockholders. Our executive officers receive a mix of time-based RSU awards and performance-based RSU awards.
The Amended and Restated 2024 Plan Combines Compensation and Governance Best Practices
The Amended and Restated 2024 Plan includes provisions that are designed to protect our stockholders’ interests and to reflect corporate governance best practices, including the following:
If Proposal No. 2 Is Not Approved, We Will Not Have Enough Shares Available under the 2024 Plan to Make Grants to Help Us Attract and Retain Top Employees
If Proposal No. 2 is approved by our stockholders, we will continue to be able to grant equity awards under the 2024 Plan (as amended and restated) to secure and retain the services of our employees, non-employee directors, and consultants, and the Amended and Restated 2024 Plan will become effective on the date of the Annual Meeting. If Proposal No. 2 is not approved by our stockholders, we will have a significantly reduced ability to use equity awards to recruit and retain highly qualified personnel and we will be substantially disadvantaged in our ability to compete in our industry. Further, if Proposal No. 2 is not approved by our stockholders, we:
For the foregoing reasons and the reasons set forth in our Proxy Statement, we urge you to approve the Amended and Restated 2024 Plan by voting “For” Proposal No. 2.
Thank you for your consideration.
Sincerely,
/s/ William M. Greenman
William M. Greenman
President, Chief Executive Officer and Director
****
VOTING MATTERS; REVOCABILITY OF PROXIES
Except as described in this supplement, the information provided in the Proxy Statement continues to apply and should be considered in voting your shares of Cerus common stock. There are no changes to the proxy card or voting instruction form previously mailed to stockholders.
If you have already voted by Internet, telephone or by mail, then you do not need to take any action unless you wish to change your vote. If you have not yet voted, please do so as soon as possible. If you have already voted and wish to change your vote based on any of the information contained in this supplement or otherwise, you may revoke your proxy and change your vote at any time before the final vote at the Annual Meeting. Important information regarding how to vote your shares of Cerus common stock and how to revoke a proxy already given is available in the Proxy Statement under the captions “Questions and Answers About these Proxy Materials and Voting—How do I vote?” and “Questions and Answers About these Proxy Materials and Voting—Can I change or revoke my vote after submitting my proxy?”, respectively. Votes already cast will remain valid and will be voted at the Annual Meeting unless changed or revoked.
As a stockholder, your vote is very important, and the Cerus Board encourages you to exercise your right to vote whether or not you plan to attend the Annual Meeting and regardless of the number of shares of Cerus common stock that you own.